Copyright © 2021 Pharmascimed. All Rights Reserved.
Perjeta
- Home
- Perjeta
NICE gives Roche’s Perjeta nod for breast cancer
- February 18, 2019
- 0
Roche has bagged NICE backing for Perjeta (pertuxumab) in the prevention of early-stage HER2-positive breast cancer from recurring after surgery, after three attempts. The new draft guidance permits Perjeta to be given...
Read moreTrending
Recent Posts
The coming age of biosimilars
- February 26, 2019
- 0
Novartis acquires game-changing cardiovascular therapy
- February 25, 2019
- 0
Roche buys gene therapy company Spark for $4.3bn
- February 25, 2019
- 0
AbbVie and Voyager Therapeutics in Parkinson’s Pact
- February 22, 2019
- 0